The first drug from Eli Lilly's new-look oncology group gets speedy review as Bilenker's team hones focus
The first drug from Eli Lilly’s Loxo buyout is nearing the finish line.
The pharma giant has received priority review for its RET inhibitor selpercatinib, setting it up for an FDA decision sometime between July and September. That will give it a further leg up on Blueprint Medicines in the race to get the first of this new class of cancer drugs approved. Blueprint has yet to submit an NDA, although it plans to this quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
